Opinion|Videos|October 31, 2024 (Updated: October 31, 2024)
Exploring Rapid-Acting Therapies in MDD: Pharmacodynamics and Treatment Evolution
Gus Alva, MD, DFAPA; Carmen Kosicek, MSN, PMHNP-BC; and Roger McIntyre, MD, FRCPC delve into FDA-approved rapid-acting treatments for MDD and TRD, focusing on the sigma-1 agonist and its pharmacodynamics. They explore treatment indications, the rapid onset of action, and how these innovations address unmet clinical needs and shift the treatment paradigm for newly diagnosed depression
Advertisement
Episodes in this series
Advertisement
Related to this article
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
2
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
3
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
4
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
5